A study conducted at Ichilov Medical Center featuring approximately 330 cancer patients treated for the disease concluded that after receiving two doses of the Pfizer vaccine, 88% of all patients developed antibodies to Corona compared to 97% in the control group made up of healthy individuals.
It was also found that both the first and second dose of the vaccine are safe for cancer patients and does not cause significant side effects even for patients undergoing active oncological treatment.